Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Hematologic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1MCRC 1Lymphopenia 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × Thymalfasin × Clear all
NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡